Alivus Life Sciences Stock Screener | Share Price & Fundamental Analysis
ALIVUS
Pharmaceuticals
Screen Alivus Life Sciences share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹898.60
▼
-14.40 (-1.58%)
Share Price BSE
₹898.90
▼
-14.10 (-1.54%)
Market Cap
₹11,056.66 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
3.66
EPS (TTM)
₹39.63
Dividend Yield
0.56%
Debt to Equity
0.01
52W High
₹1237.15
52W Low
₹860.05
Operating Margin
30.00%
Profit Margin
20.99%
Revenue (TTM)
₹2,525.00
EBITDA
₹785.00
Net Income
₹530.00
Total Assets
₹3,411.00
Total Equity
₹2,817.00
Alivus Life Sciences Share Price History - Stock Screener Chart
Screen ALIVUS historical share price movements with interactive charts. Analyze price trends and patterns.
Alivus Life Sciences Company Profile - Fundamental Screener
Screen Alivus Life Sciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ALIVUS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE03Q201024
Alivus Life Sciences Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen ALIVUS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total Assets | 3,411 | 2,850 | 2,702 | 2,471 | 1,997 | 1,726 | 1,475 | 0 |
| Current Assets | 2,335 | 1,916 | 1,850 | 1,765 | 1,399 | 1,160 | 931 | 0 |
| Fixed Assets | 955 | 805 | 781 | 590 | 573 | 546 | 456 | 0 |
| Liabilities | ||||||||
| Total Liabilities | 3,411 | 2,850 | 2,702 | 2,471 | 1,997 | 1,726 | 1,475 | 0 |
| Current Liabilities | 124 | 79 | 67 | 33 | 23 | 16 | 7 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||
| Total Equity | 2,817 | 2,332 | 2,138 | 2,054 | 753 | 402 | 88 | -1 |
| Share Capital | 25 | 25 | 25 | 25 | 2 | 2 | 2 | 0 |
| Reserves & Surplus | 2,793 | 2,308 | 2,114 | 2,030 | 751 | 400 | 86 | -1 |
Screen ALIVUS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,525 | 2,421 | 2,295 | 2,190 | 2,138 | 1,886 | 1,549 | 887 | 0 |
| Expenses | 1,741 | 1,704 | 1,609 | 1,519 | 1,507 | 1,294 | 1,065 | 639 | 0 |
| EBITDA | 785 | 717 | 686 | 671 | 631 | 592 | 484 | 248 | 0 |
| Operating Profit % | 30.00% | 29.00% | 30.00% | 30.00% | 29.00% | 31.00% | 31.00% | 28.00% | -5.00% |
| Depreciation | 67 | 61 | 54 | 42 | 38 | 33 | 29 | 19 | 0 |
| Interest | 4 | 2 | 2 | 1 | 28 | 88 | 34 | 1 | 0 |
| Profit Before Tax | 714 | 654 | 631 | 629 | 565 | 471 | 421 | 228 | 0 |
| Tax | 174 | 169 | 160 | 162 | 146 | 119 | 108 | 33 | 0 |
| Net Profit | 530 | 486 | 471 | 467 | 419 | 352 | 313 | 196 | 0 |
| EPS | 43.30 | 39.63 | 38.43 | 38.11 | 35.63 | 32.61 | 29.04 | 24.64 | -7.89 |
Alivus Life Sciences Cash Flow Screener - Liquidity Fundamentals
Screen ALIVUS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | 392 | 414 | 306 | 598 | 388 | 195 | 10 | -1 |
| Investing Activities | -616 | -117 | -147 | -122 | -69 | -51 | -9 | 0 |
| Financing Activities | -6 | -279 | -388 | -79 | -214 | -137 | 1 | 1 |
| Net Cash Flow | -230 | 18 | -228 | 397 | 106 | 8 | 2 | 0 |
Screen ALIVUS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 74.99% | 74.94% | 74.91% | 82.85% | 82.85% | 75.00% | 75.00% | 82.85% |
| FII Holding | 6.57% | 6.42% | 6.84% | 5.01% | 4.82% | 7.85% | 6.74% | 0.00% |
| DII Holding | 5.19% | 5.61% | 5.47% | 1.40% | 1.57% | 4.16% | 4.86% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 10.50% | 10.34% | 10.14% | 9.09% | 9.13% | 10.63% | 10.99% | 10.87% |
| Other Holding | 2.74% | 2.69% | 2.64% | 1.64% | 1.64% | 2.36% | 2.41% | 6.28% |
| Shareholder Count | 141,977 | 138,500 | 135,643 | 156,183 | 149,396 | 143,960 | 146,840 | 222,866 |
Alivus Life Sciences Dividend Screener - Share Yield Analysis
Screen ALIVUS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2025-March | ₹5.00 | 0.56% |
| 2024-March | ₹22.50 | 2.08% |
| 2023-March | ₹42.00 | 5.41% |
| 2022-March | ₹21.00 | 5.49% |
| 2021-March | ₹0.00 | 0.00% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
| 2016-March | ₹0.00 | 0.00% |
Alivus Life Sciences Index Membership - Market Screener Classification
Screen ALIVUS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Alivus Life Sciences Market Events Screener - Corporate Actions
Screen ALIVUS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 10.50 /share | -14.33% | ||
| Annual General Meeting | NA | -1.06% | ||
| Annual General Meeting | NA | 2.88% | ||
| Dividend | ₹ 5.00 /share | -19.97% | ||
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -0.03% |
| 2025-08-01 | 2025-08-01 | Quarterly Result Announcement | NA | 0.58% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 5.51% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | 5.35% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -8.51% |
| 2024-10-09 | 2024-10-09 | Change Of Name | NA | 0.00% |
| 2023-10-17 | 2023-10-17 | Dividend | ₹ 22.50 /share | 6.93% |
| 2023-03-24 | 2023-03-24 | Dividend | ₹ 21.00 /share | 7.96% |
| 2021-11-22 | 2021-11-23 | Dividend | ₹ 10.50 /share | -3.99% |
Alivus Life Sciences Competitors Screener - Peer Comparison
Screen ALIVUS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 412,734 | 39.30 | 54,729 | 9.71% | 10,980 | 39.06 |
| Divis Laboratories | 168,851 | 68.25 | 9,712 | 18.67% | 2,191 | 44.96 |
| Torrent Pharmaceuticals | 129,357 | 59.98 | 11,539 | 6.99% | 1,911 | 59.35 |
| Cipla | 120,557 | 22.21 | 28,410 | 7.12% | 5,291 | 42.76 |
| Dr Reddys Laboratories | 105,645 | 18.46 | 33,741 | 16.73% | 5,725 | 49.97 |
| Lupin | 95,023 | 21.85 | 22,910 | 13.74% | 3,306 | 50.10 |
| Zydus Life Science | 90,707 | 18.09 | 23,511 | 18.55% | 4,615 | 34.06 |
| Mankind Pharma | 88,846 | 50.78 | 12,744 | 20.90% | 2,007 | 40.67 |
| Aurobindo Pharma | 68,901 | 20.36 | 32,346 | 9.43% | 3,484 | 46.33 |
| Alkem Laboratories | 65,390 | 27.28 | 13,458 | 3.70% | 2,216 | 37.45 |
Alivus Life Sciences Company Announcements - News Screener
Screen ALIVUS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-01 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-18 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-03 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-01 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-27 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-13 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-06 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-06 | Unaudited Financial Results For The Second Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-30 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-29 | Closure of Trading Window | View |
| 2025-10-29 | Board Meeting Intimation for Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September 2025. | View |
| 2025-10-20 | Disclosure under Regulation 30 of LODR | View |
| 2025-10-02 | Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) | View |
| 2025-09-16 | Announcement under Regulation 30 (LODR)-Credit Rating | View |
| 2025-09-08 | Announcement under Regulation 30 (LODR)-Change in Management | View |